Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial

American Heart Journal

Volumn 170, Issue 6, 2015, Pages 1061-1069

  Nicholls, Stephen J ^a   Lincoff, A Michael ^b   Barter, Philip J ^c   Brewer, H Bryan ^d   Fox, Keith A A ^e   Gibson, C Michael ^f   Grainger, Christopher ^g   Menon, Venugopal ^b   Montalescot, Gilles ^h   Rader, Daniel ⁱ   Tall, Alan R ^j   McErlean, Ellen ^b   Riesmeyer, Jeffrey ^k   Vangerow, Burkhard ^k   Ruotolo, Giacomo ^k   Weerakkody, Govinda J ^k   Nissen, Steven E ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f HARVARD MEDICAL SCHOOL   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; BENZODIAZEPINE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; BLOOD; CEREBROVASCULAR DISORDERS; CLINICAL TRIAL; DRUG MONITORING; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASES; RISK ASSESSMENT;

ANTICHOLESTEREMIC AGENTS; BENZODIAZEPINES; CEREBROVASCULAR DISORDERS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PERIPHERAL VASCULAR DISEASES; RISK ASSESSMENT;

EID: 84949507523     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.09.007     Document Type: Article

References (44)

1. C. Baigent, L. Blackwell, J. Emberson, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. P. Libby The forgotten majority: unfinished business in cardiovascular risk reduction J Am Coll Cardiol 46 2005 1225 1228
3. P.S. MacLean, J.F. Bower, S. Vadlamudi, and et al. Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice Arterioscler Thromb Vasc Biol 23 2003 1412 1415
4. B. Foger, M. Chase, M.J. Amar, and et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice J Biol Chem 274 1999 36912 36920
5. P.M. Cazita, J.A. Berti, C. Aoki, and et al. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice J Lipid Res 44 2003 33 40
6. A.C. Casquero, J.A. Berti, A.G. Salerno, and et al. Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice J Lipid Res 47 2006 1526 1534
7. T. Hayek, L. Masucci-Magoulas, X. Jiang, and et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene J Clin Invest 96 1995 2071 2074
8. R.B. Hildebrand, B. Lammers, I. Meurs, and et al. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency Arterioscler Thromb Vasc Biol 30 2010 1439 1445
9. K.R. Marotti, C.K. Castle, T.P. Boyle, and et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein Nature 364 1993 73 75
10. A.S. Plump, L. Masucci-Magoulas, C. Bruce, and et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression Arterioscler Thromb Vasc Biol 19 1999 1105 1110
11. M. Westerterp, C.C. van der Hoogt, W. de Haan, and et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE∗3-Leiden mice Arterioscler Thromb Vasc Biol 26 2006 2552 2559
12. V.L. Herrera, S.C. Makrides, H.X. Xie, and et al. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein Nat Med 5 1999 1383 1389
13. C.W. Rittershaus, D.P. Miller, L.J. Thomas, and et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 2106 2112
14. M. Sugano, N. Makino, S. Sawada, and et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits J Biol Chem 273 1998 5033 5036
15. H. Okamoto, F. Yonemori, K. Wakitani, and et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 2000 203 207
16. L.A. Morehouse, E.D. Sugarman, P.A. Bourassa, and et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J Lipid Res 48 2007 1263 1272
17. M.L. Brown, A. Inazu, C.B. Hesler, and et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins Nature 342 1989 448 451
18. A. Inazu, M.L. Brown, C.B. Hesler, and et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation N Engl J Med 323 1990 1234 1238
19. P.J. Barter, M.J. Chapman, C.H. Hennekens, and et al. Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 2003 160 167
20. R.S. Vasan, M.J. Pencina, S.J. Robins, and et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community Circulation 120 2009 2414 2420
21. A. Ritsch, H. Scharnagl, P. Eller, and et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study Circulation 121 2010 366 374
22. S.M. Boekholdt, J.A. Kuivenhoven, N.J. Wareham, and et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study Circulation 110 2004 1418 1423
23. A. Thompson, E. Di Angelantonio, N. Sarwar, and et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 299 2008 2777 2788
24. B.F. Voight, G.M. Peloso, M. Orho-Melander, and et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
25. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, and et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
26. P.J. Barter, M. Caulfield, M. Eriksson, and et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
27. M.L. Bots, F.L. Visseren, G.W. Evans, and et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 2007 153 160
28. J.J. Kastelein, S.I. van Leuven, L. Burgess, and et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630
29. S.E. Nissen, J.C. Tardif, S.J. Nicholls, and et al. Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 2007 1304 1316
30. A.R. Tall, L. Yvan-Charvet, and N. Wang The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 27 2007 257 260
31. S.J. Nicholls, E.M. Tuzcu, D.M. Brennan, and et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation 118 2008 2506 2514
32. P. Barter Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial Am J Cardiol 104 2009 10E 15E
33. M. Vergeer, and E.S. Stroes The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors Am J Cardiol 104 2009 32E 38E
34. M.J. Forrest, D. Bloomfield, R.J. Briscoe, and et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 2008 1465 1473
35. K.K. Ray, M. Ditmarsch, D. Kallend, and et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial Eur Heart J 35 2014 1792 1800
36. T.F. Luscher, S. Taddei, J.C. Kaski, and et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial Eur Heart J 33 2012 857 865
37. Z.A. Fayad, V. Mani, M. Woodward, and et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial Lancet 378 2011 1547 1559
38. G.G. Schwartz, A.G. Olsson, M. Abt, and et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
39. C. Besler, K. Heinrich, L. Rohrer, and et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J Clin Invest 121 2011 2693 2708
40. J.C. Tardif, E. Rheaume, L.P. Lemieux Perreault, and et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib Circ Cardiovasc Genet 8 2015 372 382
41. C.P. Cannon, S. Shah, H.M. Dansky, and et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
42. S.J. Nicholls, H.B. Brewer, J.J. Kastelein, and et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
43. S. Friedrich, J.J. Kastelein, D. James, and et al. The pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins CPT Pharmacometrics Syst Pharmacol 3 2014 e94
44. K. Thygesen, J.S. Alpert, A.S. Jaffe, and et al. Third universal definition of myocardial infarction Circulation 126 2012 2020 2035